As immune cell effector therapies like CAR T-cell and bispecific T-cell engagers become more prevalent in cancer treatment, it is crucial for nurses and advanced practice providers (APPs) to understand the potential adverse effects (AEs) associated with these innovative therapies.
Experts from the 2025 Immune Cell Effector Therapies (ICE-T) Conference shed light on the importance of recognizing and managing AEs in patients undergoing these treatments. From immune effector cell–associated neurotoxicity syndrome (ICANS) to cytokine release syndrome (CRS), the landscape of AEs is evolving, especially as T-cell engager therapies expand into solid tumors like lung cancer. It is essential for healthcare professionals to stay vigilant and provide comprehensive support to patients to ensure optimal outcomes.
Read more from oncnursingnews.com